Square One Program

Program Graduates


Fall 2011

Lynxess

Founder: Nawaz Anwarudeen

Paper based lab notebooks are the most prevalent at small (startup and academic) research labs. This is in spite of the benefits offered by electronic lab notebooks (ELN). Lynxess has learned that the ELNs currently available in the market do not address the needs of small labs, are complex and cumbersome to use, and expensive. We believe that a simple, easy to use, and affordable ELN is technologically feasible and viable. With such a notebook we seek to empower researchers at small research labs to collaborate, communicate, document, advance, and accelerate their research.

 

Nanopore Diagnostics, LLC

Founder: Christoph Bausch

There is an urgent need for a blood-based molecular diagnostic test to screen for early stage diseases such as cancer. Nanopore Diagnostics, LLC is a best-generation platform technology for molecular diagnostics. Our platform uses a proprietary capture technology coupled to nanopore-based detection sensor that provides label-free single molecule detection, higher accuracy and lower costs per assay than precedent molecular diagnostic tests. The developed technology is a highly versatile and simple platform that can be used to detect a variety of single stranded nucleic acid-based biomarkers from circulating blood for the diagnosis and monitoring of human diseases.

 

Entrepreneur: Metin Bilgin

We have isolated a novel compound (DB709) from wild-type soybean Glycine tomentella, that acts as a biofungicide that is >95% effective against Phakopsora pachyrhizi, the causing agent of “Asian soybean rust” (ASR) disease (U.S. Patent App. No. 12/370,373, U.S.P.T.O. on 2/12/2009). This molecule inhibits fungal spore growth and disease formation at micromolar concentrations. The technology is still at the laboratory stage and needs some improvement in bulk production. 

 

Entrepreneur: Gregg Bogosian

My concept is to mine the microbial world for useful organisms, genes, and other tools. Products would include the organisms themselves (for example, as bioinoculants), compounds produced by the organisms (for example, biofuels), genes from the organisms (for example, encoding enzymes useful in bioconversions), and tools constructed from the organisms (for example, gene expression tools).

 

Entrepreneur: Kay Broschat

As a consequence of the recent recession, investment in new ventures and IPO’s waned as investors grew more conservative. This response had the consequence of stalling drugs in the early stages of development by small biotechnology companies as funding evaporated. These stranded assets are the core of our opportunity. Our business model is to establish a back-loaded licensing agreement to develop an abandoned asset with a company that has taken the asset to completion of Phase I safety evaluation but is now seeking to out-license the asset. After identifying the asset we will fill the missing data with preclinical and clinical efficacy data, including Phase II proof of concept and eventually license the asset to a larger pharmaceutical company for completion of Phase III registration trials. We have identified the first candidate to advance, and have additional candidates that will fit this business model. 

 

TheraMind Research

Founder: Robert Cormier

TheraMind Research is developing a novel anti-epileptic compound.

 

Entrepreneur: Amos Danielli

Magnetic modulation biosensing (MMB) is a novel technology for rapid, simple and sensitive detection of biological targets in homogeneous solution at low concentrations. In general, any assay that produces fluorescent light as a result of the biorecognition event can utilize the MMB system. MMB relies on coupling magnetic beads to the fluorescent-labeled probes and applying an alternating magnetic field gradient to condense the probes into the detection area and set them in a 1-D periodic motion, in and out of an orthogonal laser beam. Phase-locked detection of the resulted periodic fluorescent light provides high sensitivity without any washing or separation steps. Rapid detection of the Ibaraki virus without biological amplification and rapid detection of a protein (0.48 pg of human interleukin-8) were already demonstrated.

 

MediBeacon, Inc.

Entrepreneur: Rick Dorshow

MediBeacon Inc. is a pharmaceutical company employing its own intellectual property to research and commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. The MediBeacon portfolio includes the optical renal function monitor which is at the brink of clinical trials, several projects at the research stage, and even more at the concept and/or feasibility stage. In addition, MediBeacon will manufacture dye bioconjugates from its proprietary fluorophore platform for the in vitro and in vivo research markets and distribute product through established vendors. This will provide MediBeacon with a near-term revenue stream, while maintaining the corporate focus on in vivo human applications.

 

Pada Medical Products

Founders: Debra Shetka & Jim Leary


Pada Medical Products is focused on improving wound care for people with chronic wounds. The company’s flagship product is a compact device that promises to revolutionize the treatment of chronic wounds. Chronic wounds are a problem that has reached epidemic proportions worldwide, particularly in people with diabetes, vascular disease, and limited mobility. Chronic wounds are a staggering burden to the United States and global healthcare systems. In the United States alone, treatment costs exceed $25 billion per year to care for the estimated 6.5 million adults suffering from chronic wounds. For people with diabetes, chronic wounds result in 80,000 lower limb amputations per year.  Every 30 seconds, somewhere in the world, a limb is lost as a consequence of diabetes. Pada Medical was founded in 2010 by Debra Shetka, Jim Leary, and Steve Kelley. The team has a combined 80 years of experience in life sciences, law, medical device engineering, and the health care industry. A prototype device is currently being refined for clinical testing and commercial release. A pipeline of other products is under development.

 

Vet Med Pharmaceutical Development

Entrepreneur: Alan MacInnes

Vet Med Pharmaceutical Development (VMPD) is an animal health product development company that will develop innovative new formulations of drugs currently used for human disease, for use under prescription in companion animals. VMPD will specifically target companion animal disease indications that have a high unmet treatment need and will provide 'pet friendly' drugs that are proven to work safely in the target species, are formulated in a way to provide ease of administration, and are available in doses that meet the needs of the highly variable weight profile of companion animal pets. We initially plan to offer veterinarians a stream of newly developed animal drugs through license agreements with development partners and ultimately offer a line of branded products specifically designed for dispensing through the small animal veterinary practice.

 

SurgON

Entrepreneur: Bill Macneil

"SurgON" (SURGical Open Network) is a communication infrastructure for control and data integration of operating room devices into a central network hub for centralized touch screen access or projection to remote specialist for teleconsultation. By implementing a uniform integration strategy, connections into the consolidated display and control screen can be made dynamically to streamline access to technology in emergent or unanticipated clinical scenarios. With SurgON technology, the aim is to provide a common network foundation between vendors for surgical device communications to enable a truly "universal remote" for the OR.

 

Sci-Engi-Medco Solutions Inc.

Founder: Raghu S. Pandurangi, M.Sc.Ed; Ph.D. (Former Technical Fellow from Covidien)

Sci-Engi-Medco is developing a technology to improve the effectiveness of chemotherapy for breast cancer. In particular, the technology will focus on enhancing the actions of Avastin™. Dysregulation of apoptosis is responsible for the failure of Avastin™ in 66 % of breast cancer patients. Our prime molecule is natural, biocompatible, and targeted specifically to the tumor via a priori activation of dysregulated apoptosis signal pathway. With the availability of prime drug candidates and limited data on the proof of concept, Sci-Engi-Medco is seeking $ 200,000 to synthesize and scale up the compound and perform validation on different types of breast cancers to capture the $1 billion market vacated by the withdrawal of Avastin™ by the FDA. The technology is called “A priori Activation of Apoptosis of Tumor Technology (AAATT) and it can be licensed to many types of cancers and drugs since AAATT is a pretreatment strategy adjunct to the existing chemotherapy.

 

WPG, LLC

Founder: Mukund Parthasarathy

WPG, LLC is a pet food research and consulting company focusing on pet food nutrition and taste. Nutraceuticals is a growing area in the field of human and pet health. Many nutraceuticals studies are being conducted in small mammals such as rats, mice, and humans. The positive, or not so positive, findings are being extrapolated to pets. Currently there are very few nutraceutical related projects being conducted by large pet food companies. This is because of opposition to invasive research by organizations like PETA and other animal rights activists. There are many pet products in the market with unsubstantiated claims and most of these products are manufactured by small and mid size companies. The goal of WPG is to pursue nutraceutical projects that can address the major problems faced by pets and pet owners.

 

Allergy Sciences

Founder: Das Prayaga

A novel peptide based vaccine for seasonal allergies which may be useful as a platform technology for prognosis, diagnosis, and therapy for allergy in humans and other animals. We have identified a novel unique peptide associated with protection from seasonal allergies in horses. Recurrent air way obstructions (RAO) are an animal model for seasonal allergies and mimic symptoms similar to that in humans. High level of natural protective antibodies to this peptide is found in animals that are resistant to RAO. Computational sequence analysis of the peptide found it to have significant sequence homology to proteins from some of the well-know environmental allergens such as Aspergillus.

 

Health Benefit Technologies

Entrepreneur: Raj Riswadkar

Health Benefit Technologies is in the business of reducing the cost of care in managing complex, chronic diseases. Our first product is a care coordination platform, 'iControldiabetes', (iCD) aimed at reducing the costs of care of diabetes whilst increasing 5 star scores of Medicare, Medicaid plans, ACOs, and other providers and payers. Successfully tested on 10,000 patients, iCD is our diabetes care coordination platform designed to help the more than 25 million diabetics in the United States manage their complex care in a simple and cost effective manner compared to the current standard of care.  As a web served, patient and caregiver friendly, physician designed for point-of-care, ready to deploy system, we believe that iCD can add value to payers such as MCOs, PBMs, states, Medicare and Medicaid and many others, not to forget global applications aimed at the over 137 million global patient population.

 

AF Innovation, LLC

Founder: Qun Sha

The development of advanced diagnostic and therapeutic instruments and equipments for electrophysiology (EP) procedures represents an activity of central importance to improvements in heart rhythm disorder patients. A key challenge is in the realization of bio-compatible interfaces between the classes of semiconductor and sensor technologies that might be useful in this context and the soft, curvilinear surfaces of the body, such as coronary sinus (CS). We will be working with relevant biomedical engineers to develop a solution based on biocompatible materials and devices that integrate directly with the thin elastic membranes of otherwise conventional multimodel CS catheters, to provide such CS therapy in Atrial fibrillation patients. The company is also investigating other new EP products to improve health care for cardiac arrhythmia.

 

Kypha

Entrepreneur: Chad Stiening

Kypha is an early-stage biotechnology company developing inflammation-monitoring diagnostics. The company has used primarily grant funding to develop a working prototype of its first product, the CompAct™ Test. It is a rapid point-of-care blood test that measures inflammation to aid in the diagnosis and monitoring of autoimmune and immunologic disorders. The Company is completing product development and clinical validation studies and anticipates FDA clearance and market entry in the next 12-18 months.

 

Array Bridge, Inc.

Founder: Xing Wang

Array Bridge, Inc. (“Array Bridge”) is an ‘analytical tools’ company focusing on the development and commercialization of immunoassays (IA) that are used for the research, development, and production of bio-therapeutic drugs. Its first products are kits that will quantitate the level of contaminating Host Cell Proteins (HCPs), a critical regulatory specification for bio-therapeutics and antibody arrays used to analyze therapeutic protein conformational changes. Leveraging revenue from initial product sales and investment capital, Array Bridge will build a portfolio of unique, high value, commercially validated assets.